Certara Completes Acquisition of Chemaxon

Rhea-AI Summary

Certara, Inc. (Nasdaq: CERT), a leader in model-informed drug development, has completed the acquisition of Chemaxon, a developer of scientific informatics software for in-silico research in the life sciences industry. The combined organization aims to offer improved predictive biosimulation and scientific informatics capabilities to enhance decision-making from discovery through commercialization.

Key points:

• Integration plans include incorporating Chemaxon's chemistry structures, calculators, and predictors into Certara's D360 applications and Simcyp™ PBPK Simulator.
• Long-term plans involve leveraging Certara.AI's specialized GPT capabilities and expanding pharmacokinetics and pharmacodynamics knowledge in drug discovery processes.
• Chemaxon is expected to generate software revenue exceeding $20 million in 2024.
• Certara will update its 2024 guidance to include Chemaxon's contribution in its third-quarter earnings report in November.

Positive

• Acquisition of Chemaxon enhances Certara's capabilities in scientific informatics and biosimulation
• Expected to improve prediction accuracy and decision-making in drug discovery and development
• Chemaxon projected to generate over $20 million in software revenue for 2024
• Potential for increased scientific innovation success rates in life sciences industry
• Plans to leverage Certara.AI's specialized GPT capabilities for drug discovery

Negative

• None.

Insights

Financial Analyst

The acquisition of Chemaxon by Certara (NASDAQ: CERT) is a significant move that could enhance Certara's position in the drug development software market. With Chemaxon's expected $20 million in software revenue for 2024, this deal will likely have a positive impact on Certara's financial performance. The integration of Chemaxon's scientific informatics capabilities with Certara's biosimulation expertise could create a more comprehensive offering, potentially driving increased market share and revenue growth. Investors should watch for the updated 2024 guidance in Certara's Q3 earnings report to gauge the full financial impact of this acquisition. The combined entity's ability to offer enhanced predictive capabilities may lead to improved client retention and attraction of new customers in the competitive life sciences software market.

Tech Expert

This acquisition strategically positions Certara at the intersection of biosimulation and scientific informatics. The integration of Chemaxon's in-silico research tools with Certara's modeling solutions creates a powerful synergy that could accelerate drug discovery and development processes. Key technological benefits include incorporating precision chemistry structures into Certara's D360 and Simcyp™ PBPK Simulator, potentially enhancing prediction accuracy. The long-term plan to leverage Certara.AI's life sciences GPT capabilities with Chemaxon's products like Design Hub and JChem Engines is particularly intriguing. This AI-driven approach could revolutionize how pharmacokinetics and pharmacodynamics are applied in early-stage drug discovery, potentially reducing time-to-market and development costs for pharmaceutical companies.

The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization.

RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has completed the acquisition of Chemaxon.

Chemaxon develops leading scientific informatics software products used by the life sciences industry for in-silico research. Certara develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties of large and small molecules.

"Combining Chemaxon’s expertise with Certara’s biosimulation capabilities provides life sciences companies with unique solutions to enhance productivity and increase their scientific innovation success rates,” said William Feehery, Certara’s CEO. “Together, we offer scientists more precise insights throughout drug discovery and development.” 

Near-term priorities for the combined organization include incorporating precision chemistry structures, calculators, and predictors into the Certara D360 scientific informatics applications and Simcyp™ PBPK Simulator for improved prediction accuracy. Longer-term plans include leveraging Certara.AI’s life sciences specialized GPT capabilities and bringing knowledge of pharmacokinetics and pharmacodynamics more broadly into the drug discovery process and Chemaxon products including Design Hub and JChem Engines.

“Our teams are excited to have an even greater impact on drug discovery and development practices,” said Richard Jones, Chemaxon CEO. “As pipelines shift to precision medicine therapies, accurate scientific predictions and biosimulation are more crucial to success than ever.” 

In 2024, Chemaxon is expected to generate software revenue greater than $20 million. Certara will update its 2024 guidance to include the contribution from Chemaxon when the Company reports third-quarter earnings in November.

A “frequently asked questions” document regarding the transaction is available on the Company’s investor relations website.

About Certara 

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com. 

About Chemaxon 

Chemaxon is a leading cheminformatics company that provides platforms, applications, and solutions to handle chemical entities in life sciences, biotechnology, agrochemicals, new materials, education, and other research industries. Its products and services help the capture and processing of chemical information that increases its value and results in more efficient decision-making for life sciences and other R&D environments. Learn more at chemaxon.com.  

Certara Contact: 
Sheila Rocchio 
sheila.rocchio@certara.com  

Media Contact: 
Alyssa Horowitz 
certara@pancomm.com 

FAQ

What is the significance of Certara's acquisition of Chemaxon?

The acquisition combines Certara's biosimulation capabilities with Chemaxon's scientific informatics expertise, offering life sciences companies improved tools for drug discovery and development. This is expected to enhance productivity and increase scientific innovation success rates in the industry.

How much revenue is Chemaxon expected to generate in 2024?

Chemaxon is projected to generate software revenue exceeding $20 million in 2024.

When will Certara (CERT) update its 2024 guidance to include Chemaxon's contribution?

Certara plans to update its 2024 guidance, including Chemaxon's contribution, when the company reports its third-quarter earnings in November.

What are the near-term integration plans for Certara and Chemaxon?

Near-term plans include incorporating Chemaxon's precision chemistry structures, calculators, and predictors into Certara's D360 scientific informatics applications and Simcyp™ PBPK Simulator to improve prediction accuracy.